Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)

Jonathan I. Silverberg(George Washington University), Andreas Wollenberg(University Hospital Augsburg), Andrew Pink, Valéria Aoki(Universidade de São Paulo), Yousef Binamer(Alfaisal University), Brian Calimlim(AbbVie (United States)), Petra Staubach(Johannes Gutenberg University Mainz), Alvaro Moreira(Icahn School of Medicine at Mount Sinai), Ayman Grada(University Hospitals of Cleveland), Chao Li(Eli Lilly (United States)), Brad Glick(Mount Sinai Medical Center), Melinda Gooderham(Queen's University), Norito Katoh(Kyoto Prefectural University of Medicine), Wan‐Ju Annabelle Lee(AbbVie (United States))
Dermatology and Therapy
July 14, 2025
10.1007/s13555-025-01485-0
Cited by 4

Related Papers

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
|The Lancet|2021|538